BPTH (Bio-Path Holdings) EBIT per Share: $-0.67 (TTM As of Mar. 2026)


What is Bio-Path Holdings EBIT per Share?

Bio-Path Holdings BPTH +45.96% EBIT per Share is $-0.67 as of Mar. 2026. The stock has 1 warning sign investors should review. Among 1,181 Biotechnology companies, Bio-Path Holdings ranks better than 82.73% on this metric.

Bio-Path Holdings's EBIT per Share for the three months ended in Mar. 2026 was $-0.03. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.67.

During the past 3 years, the average EBIT per Share Growth Rate was 45.60% per year. During the past 5 years, the average EBIT per Share Growth Rate was 33.50% per year. During the past 10 years, the average EBIT per Share Growth Rate was 30.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Bio-Path Holdings's EBIT per Share or its related term are showing as below:

BPTH' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -26.6   Med: 2.2   Max: 51.1
Current: 45.6

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Bio-Path Holdings was 51.10% per year. The lowest was -26.60% per year. And the median was 2.20% per year.

BPTH's 3-Year EBIT Growth Rate is ranked better than
82.73% of 1181 companies
in the Biotechnology industry
Industry Median: 15.5 vs BPTH: 45.60

Bio-Path Holdings's EBIT for the three months ended in Mar. 2026 was $-0.25 Mil.

Bio-Path Holdings  (OTCPK:BPTH) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Bio-Path Holdings EBIT per Share Related Terms

Bio-Path Holdings EBIT per Share Historical Data

* Premium members only.

The historical data trend for Bio-Path Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Path Holdings EBIT per Share Chart

Bio-Path Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -56.81 -31.08 -38.19 -33.14 -5.00

Bio-Path Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.46 -0.40 -0.55 -0.10 -0.03

Bio-Path Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Bio-Path Holdings's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

EBIT per Share(A: Dec. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-11.992/2.401
=-4.99

Bio-Path Holdings's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.245/9.342
=-0.03

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.67 mean?
Bio-Path Holdings (BPTH) has a EBIT per Share of $-0.67 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bio-Path Holdings and its competitors. According to the industry distribution chart, Bio-Path Holdings ranks #204 out of 1181 companies in the Biotechnology industry, placing it in the top 17.3%.
Is Bio-Path Holdings' EBIT per Share too high?
Bio-Path Holdings' current EBIT per Share is $-0.67. Based on the distribution chart, Bio-Path Holdings ranks #204 out of 1181 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Bio-Path Holdings' EBIT per Share compare to VBIO and HEPA?
According to the Biotechnology industry distribution chart, Bio-Path Holdings ranks #204 out of 1181 companies for EBIT per Share. This places Bio-Path Holdings in the top 17% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bio-Path Holdings and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Path Holdings's current EBIT per Share is $-0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current EBIT per Share of $-0.67. The current EBIT per Share is $-0.67. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current EBIT per Share is $-0.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Path Holdings Business Description

Address No. 2407, 625 Stanwix Street, Pittsburgh, PA, USA, 15222
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.